Jonathan McDonagh, MD
Vascular Surgery · Anchorage, AKNPI 1972609949
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,735 of the $8,544 with a category attached, or 78.8%. 27 manufacturers reported payments, led by Abbott at 40.4% of the total.
Across 143 payments — averaging $59.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Medtronic$1K
- Edwards Lifesciences$1K
- Boston Scientific$887
- Abiomed$319
- Amgen$229
- plus $1K from 21 others
What the payments were for
- Travel & lodging$1,80921%
- Food & beverage$6,73579%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 33 | $3,452 |
| Medtronic(2 entities) | 14 | $1,293 |
| Edwards Lifesciences | 18 | $1,240 |
| Boston Scientific | 22 | $887 |
| Abiomed | 5 | $319 |
| Amgen | 9 | $229 |
| E.r. Squibb & Sons, L.L.C. | 9 | $156 |
| Shockwave Medical, Inc | 1 | $125 |
| Teleflex LLC | 1 | $97 |
| Novartis | 5 | $97 |
| Cleerly, Inc. | 1 | $93 |
| Getinge USA Sales, LLC | 1 | $72 |
| Bard Peripheral Vascular, Inc. | 2 | $71 |
| W. L. Gore & Associates, Inc. | 1 | $46 |
| Cardiovascular Systems Inc. | 3 | $43 |
| Pfizer | 2 | $42 |
| AstraZeneca | 2 | $38 |
| Johnson & Johnson | 3 | $38 |
| Stryker | 1 | $33 |
| Biotronik Inc. | 2 | $29 |
| Merck | 1 | $27 |
| Penumbra, Inc. | 2 | $25 |
| Philips North America LLC | 1 | $23 |
| Bayer | 1 | $23 |
| Siemens Medical Solutions USA, Inc. | 1 | $19 |
| Portola Pharmaceuticals, LLC | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRICLIP$1,296
- Mitra Clip system$709
- COREVALVE EVOLUT R$569
- MitraClip$443
- IN.PACT Admiral$240
- Impella$236
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$234
- Edwards SAPIEN 3 Transcatheter Heart Valve$208
- PASCAL$157
- CoreValve Evolut$155
- Vascular Lithotripsy$125
- COROFLOW$119
- Xience Sierra Coronary Stent System$112
- HeartWare HVAD$106
How this compares
Too few vascular surgery providers in Alaskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 111 | $166,349 |
| XareltoRivaroxaban | 26 | $39,081 |
| Repatha SureclickEvolocumab | 50 | $38,096 |
| EntrestoSacubitril/Valsartan | 25 | $35,927 |
| JardianceEmpagliflozin | 14 | $23,824 |
| BrilintaTicagrelor | 18 | $8,703 |
| Atorvastatin Calcium | 224 | $4,806 |
| ClopidogrelClopidogrel Bisulfate | 191 | $4,138 |
| Metoprolol Succinate | 200 | $3,763 |
| Rosuvastatin Calcium | 170 | $2,789 |
| Losartan Potassium | 93 | $1,820 |
| Valsartan | 25 | $1,455 |
| Ezetimibe | 43 | $1,369 |
| Eplerenone | 11 | $1,320 |
| Amlodipine Besylate | 103 | $1,211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $42 | $166,349111 claims |
| Johnson & JohnsonXarelto | $38 | $39,08126 claims |
| NovartisEntresto | $97 | $35,92725 claims |
| AstraZenecaBrilinta | $38 | $8,70318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few vascular surgery providers in Alaskaon file to place this against a meaningful peer group, so we don't.
Other vascular surgery in Anchorage
- Jonathan BarnesAnchorage$8K
- Stanley WatkinsAnchorage$7K
- Priya PatelAnchorage$6K
- Galimat KhaidakovaAnchorage$5K
- Seth KraussAnchorage$1K
- April RodriguezAnchorage$997
- Milan BajmocziFairbanks$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.